Melatonin / Risk Cancer Research Results

MEL, Melatonin: Click to Expand ⟱
Features:
Hormone in the body made by pineal gland.
• Melatonin is a potent antioxidant. It neutralizes reactive oxygen species (ROS) and reactive nitrogen species (RNS), which are involved in DNA damage and cancer progression.
• Melatonin has been shown to modulate apoptotic pathways by influencing mitochondrial permeability, cytochrome c release, and caspase activation.
• In several cancer cell models, melatonin appears to promote apoptosis in malignant cells while sparing normal cells.

The most well-known indolamines are serotonin and melatonin, both of which play significant roles in regulating mood, sleep, and overall mental well-being.

Melatonin doses (20 mg to even 40 mg per day), often given as an adjuvant treatment for cancer.
-The plasma half-life of melatonin is generally in the range of approximately 20 to 60 minutes
-It has been suggested that administering melatonin at the appropriate phase of the circadian cycle may enhance its anti-tumor activity and reduce the side effects of chemotherapy and radiation therapy.

Bio-availability: Oral melatonin has a low and variable bio-availability (often estimated between 3% and 33%), which means that only a fraction of the ingested dose reaches the bloodstream unchanged.

For proOxidant effect might need >10uM, which might be 100mg dose (assuming 10% bio-availability) Might also be required X10 levels?
-It remains unknown whether the pro-oxidant action exists in vivo. the vast majority of evidence indicates that melatonin is a potent antioxidant in vivo even at pharmacological concentrations.

Interactions:
-Melatonin could potentially add to the blood pressure–lowering properties of antihypertensive drugs.
-Patients using insulin should be monitored for changes in blood glucose levels.
-Melatonin might interact with drugs like warfarin, aspirin, or clopidogrel.(antiplatelet)


Melatonin Cancer Relevant Pathways
Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 Circadian signaling (MT1 / MT2 receptors) ↓ proliferative circadian disruption ↑ circadian synchronization Driver Chronobiology normalization Melatonin restores circadian control; cancer cells lose growth advantages from circadian dysregulation
2 Reactive oxygen species (ROS) ↓ ROS (baseline); context-dependent ↑ stress signaling ↓ ROS (strong buffering) Driver Antioxidant dominance with signaling effects Melatonin is a potent direct and indirect antioxidant; cancer cells may still undergo stress-mediated growth inhibition
3 Mitochondrial function ↓ metabolic flexibility; ↑ apoptosis sensitivity ↑ mitochondrial efficiency Secondary Mitochondrial stabilization vs vulnerability Melatonin improves mitochondrial function in normal cells while limiting metabolic plasticity in cancer cells
4 Estrogen signaling (ERα modulation) ↓ estrogen-driven proliferation ↔ minimal Secondary Hormone-dependent growth suppression Particularly relevant in breast and hormone-responsive cancers
5 NF-κB signaling ↓ inflammatory / survival signaling ↓ inflammatory tone Secondary Anti-inflammatory modulation NF-κB suppression contributes to reduced tumor-promoting inflammation
6 Cell cycle regulation ↓ proliferation / ↑ arrest ↔ spared Phenotypic Cytostatic growth control Growth inhibition reflects upstream circadian and hormonal effects
7 Apoptosis sensitivity ↑ sensitivity to apoptosis (chemo/RT) ↓ apoptosis Phenotypic Therapy sensitization Melatonin enhances response to chemo- and radiotherapy while protecting normal tissue


Risk, Risk: Click to Expand ⟱
Source:
Type:
Risk: by definition reduces risk of disease or cancer.
Down Target direction of risk indicates lower cancer risk.
ChemoPreventive also mean lower cancer risk. But for Chemopreventive an up arrow indicates more preventive.
Cancer Risk Impact Score (CRIS)
CRIS scale:
–5 = very strong risk reduction
–4 = strong risk reduction
–3 = moderate risk reduction
–2 = modest risk reduction
–1 = weak / context-dependent
0 = neutral

CRIS Exposure / Compound Evidence Cancers Notes
-5 Exercise (overall) VStrong Hum BC, CRC, Endo, PCa, Liv
-5 Aerobic + resistance VStrong Hum Broad inc + mort
-4 Aerobic exercise (mod–vig) VStrong Hum BC, CRC, Endo
-4 Resistance training (alone) Strong Hum BC, CRC
-3 High-intensity interval training Mod–Strong Hum BC, CRC
-2 NEAT / low-intensity activity Moderate Hum CRC
-5 Cruciferous vegetable pattern Strong Hum Lung, CRC, BC, PCa
-5 Sunlight exposure (physiologic) Strong Hum CRC, BC, PCa
-4 Fasting (metabolic pattern) Strong Mech + Hum BC, CRC, PCa
-4 Curcumin Hum + Pre GI, BC, PCa
-4 Sulforaphane Hum + Pre Lung, CRC, BC
-4 PEITC Hum + Pre Lung, CRC, PCa
-4 EGCG (tea matrix) Strong Hum GI, PCa, BC
-4 Lycopene Strong Hum PCa
-4 Apigenin Pre + Diet Hum BC, PCa, CRC
-4 Luteolin Pre + Diet Hum Lung, CRC, BC
-4 Kaempferol Diet Hum Ov, Panc, Lung
-4 Fisetin Pre + Early Hum CRC, PCa, Mel
-4 Ellagic acid → Urolithin A Hum (microbiome) CRC, PCa, BC
-3 Omega-3 (EPA/DHA) Strong Hum CRC, BC
-3 Vitamin D3 (supp) Obs + RCT CRC, BC
-3 Garlic (allicin) Mod Hum GI
-3 Mushroom beta-glucans Hum adjunct GI, BC
-3 Melatonin Hum + Mech BC, PCa
-3 Coffee (whole) Strong Hum Liv, Endo
-2 Quercetin Limited Hum Lung, CRC
-2 Resveratrol Limited Hum CRC, BC
-2 I3C / DIM Mod Hum BC, Cerv
-2 Thymoquinone Early Hum BC, CRC
-2 Beta-carotene (food) Hum Lung
-1 Vitamin K2 (MK-4/7) Limited Hum Liv, PCa
-1 Boron Obs PCa, Lung
0 Vitamin C (oral) Strong Hum
0 Genistein (soy) Strong Hum BC, PCa
0 Selenium (diet) Mixed Hum PCa
0 Capsaicin Mixed Gastric
+2 Vitamin E (alpha only) Strong RCT PCa
+2 Green tea extract (high-dose) Case reports Liv
+4 Beta-carotene (supplement) Strong RCT Lung (smokers)
+5 Alcohol (ethanol) Strong Hum BC, Liv, Eso
Evidence Hum human data VStrong very strong Strong strong Mod moderate Obs observational Pre preclinical RCT randomized controlled trial Mech mechanistic Adjunct adjunct clinical use


Scientific Papers found: Click to Expand⟱
1786- MEL,    What is known about melatonin, chemotherapy and altered gene expression in breast cancer (Review)
- Review, NA, NA
AntiTum↑, Risk↓, ChemoSen↑,
1779- MEL,    Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review
- Review, BC, NA
QoL↑, OS↑, Dose∅, antiOx↑, ROS↑, SOD↑, Catalase↑, GPx↑, Risk↓, NK cell↑, IL1β↓, IL6↓, TNF-α↓, radioP↑, chemoP↑, TumVol↓, TumMeta↓, angioG↓, ChemoSen↑, eff↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   ROS↑, 1,   SOD↑, 1,  

Migration

TumMeta↓, 1,  

Angiogenesis & Vasculature

angioG↓, 1,  

Immune & Inflammatory Signaling

IL1β↓, 1,   IL6↓, 1,   NK cell↑, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance

ChemoSen↑, 2,   Dose∅, 1,   eff↑, 1,  

Clinical Biomarkers

IL6↓, 1,  

Functional Outcomes

AntiTum↑, 1,   chemoP↑, 1,   OS↑, 1,   QoL↑, 1,   radioP↑, 1,   Risk↓, 2,   TumVol↓, 1,  
Total Targets: 22

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Risk, Risk
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:122  Target#:785  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page